4/A: Myomo CEO Paul Gudonis Increases Stake via Salary Exchange

Myomo CEO Paul Gudonis received 16,666 restricted stock units as part of a voluntary program to exchange 10% of his salary for equity at a premium.

Summary

• CEO Paul Gudonis was granted 16,666 Restricted Stock Units (RSUs) on April 10, 2026.
• The grant is part of a Board-approved program allowing employees to exchange 10% of their salary for RSUs.
• The RSUs were issued at a grant date fair value equal to 115% of the salary foregone.
• This specific transaction covers the exchange of three months of the CEO's salary.
• The RSUs are scheduled to vest in their entirety on July 9, 2026.
• Following this transaction, Paul Gudonis beneficially owns ,1,277,316 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal because the CEO is increasing his personal stake in the company at a time when he could have opted for cash, though the dilution is a minor offset.

Positives

• The CEO is demonstrating confidence in the company by opting for equity over cash compensation.
• The program preserves corporate cash by reducing salary expenses.
• The 15% premium on the salary-to-equity exchange incentivizes executive alignment with shareholder interests.

Negatives

• The issuance of new RSUs results in minor dilution for existing shareholders.
• The vesting period is relatively short, with full vesting occurring in less than three months from the grant date.

Risks

• The value of the compensation is tied to the market price of MYO stock, exposing the executive to market volatility.
• Short-term vesting schedules may not provide the same long-term retention incentive as multi-year vesting plans.

Future Outlook

The CEO's decision to take a portion of his compensation in equity suggests a positive internal outlook on the company's valuation leading into mid-2026.

Management Comments

• The reporting person elected to forego 10% of salary in exchange for a grant of RSUs with a grant date fair value of 115% of such salary exchanged.

Industry Context

StockSavvy.ai notes that salary-for-equity swaps are common in micro-cap medical technology companies to manage burn rates while signaling management's commitment to the company's growth trajectory.

Comparison to Industry Standards

• The 15% premium for salary exchange is a standard incentive used by small-cap companies to encourage executive participation in equity programs.
• The 10% salary reduction is comparable to cash-preservation strategies seen at other medical device firms like Ekso Bionics or ReWalk Robotics during growth phases.

Corporate Governance

Related Party Transactions

• Grant of 16,666 RSUs to CEO Paul Gudonis as part of an executive compensation program.

Stakeholder Impact

• Shareholders benefit from the CEO's increased skin in the game and the company's cash preservation.
• Minor dilution occurs for existing shareholders due to the issuance of new equity units.

Next Steps

• Vesting of 16,666 RSUs on July 9, 2026.

Key Dates

Recommendation

The transaction is a routine part of a compensation program and, while positive, does not represent a significant enough change in fundamentals or a large enough open-market purchase to warrant a change in rating.

Keywords

Myomo, MYO, Paul Gudonis, Insider Trading, Restricted Stock Units, Executive Compensation, Salary Exchange, Medical Devices